These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
205 related items for PubMed ID: 22717544
1. Regression of ECG-LVH is associated with lower risk of new-onset heart failure and mortality in patients with isolated systolic hypertension; The LIFE study. Larstorp AC, Okin PM, Devereux RB, Olsen MH, Ibsen H, Dahlöf B, Kjeldsen SE, Wachtell K. Am J Hypertens; 2012 Oct; 25(10):1101-9. PubMed ID: 22717544 [Abstract] [Full Text] [Related]
4. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: The Losartan Intervention for Endpoint reduction in Hypertension (LIFE) Study. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Dahlof B, Losartan Intervention for Endpoint reduction in hypertension Study Investigations. Circulation; 2003 Aug 12; 108(6):684-90. PubMed ID: 12885747 [Abstract] [Full Text] [Related]
5. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study. Okin PM, Wachtell K, Kjeldsen SE, Julius S, Lindholm LH, Dahlöf B, Hille DA, Nieminen MS, Edelman JM, Devereux RB. Circ Arrhythm Electrophysiol; 2008 Dec 12; 1(5):337-43. PubMed ID: 19808428 [Abstract] [Full Text] [Related]
6. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. Wachtell K, Okin PM, Olsen MH, Dahlöf B, Devereux RB, Ibsen H, Kjeldsen SE, Lindholm LH, Nieminen MS, Thygesen K. Circulation; 2007 Aug 14; 116(7):700-5. PubMed ID: 17664372 [Abstract] [Full Text] [Related]
7. Regression of electrocardiographic left ventricular hypertrophy is associated with less hospitalization for heart failure in hypertensive patients. Okin PM, Devereux RB, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Dahlöf B, LIFE Study Investigators. Ann Intern Med; 2007 Sep 04; 147(5):311-9. PubMed ID: 17785486 [Abstract] [Full Text] [Related]
10. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIFE). Okin PM, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Nieminen MS, Edelman JM, Dahlöf B, Devereux RB, LIFE Study Investigators. Circulation; 2009 Apr 14; 119(14):1883-91. PubMed ID: 19332468 [Abstract] [Full Text] [Related]
11. Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study. Okin PM, Devereux RB, Gerdts E, Snapinn SM, Harris KE, Jern S, Kjeldsen SE, Julius S, Edelman JM, Lindholm LH, Dahlöf B, LIFE Study Investigators. Circulation; 2006 Mar 28; 113(12):1588-96. PubMed ID: 16534012 [Abstract] [Full Text] [Related]
15. Serial assessment of the electrocardiographic strain pattern for prediction of new-onset heart failure during antihypertensive treatment: the LIFE study. Okin PM, Oikarinen L, Viitasalo M, Toivonen L, Kjeldsen SE, Nieminen MS, Edelman JM, Dahlöf B, Devereux RB, LIFE Study Investigators. Eur J Heart Fail; 2011 Apr 28; 13(4):384-91. PubMed ID: 21239405 [Abstract] [Full Text] [Related]
16. Effect of hemoglobin levels on cardiovascular outcomes in patients with isolated systolic hypertension and left ventricular hypertrophy (from the LIFE study). Smebye ML, Iversen EK, Høieggen A, Flaa A, Os I, Kjeldsen SE, Olsen MH, Chattopadhyay A, Hille DA, Lyle PA, Devereux RB, Dahlöf B. Am J Cardiol; 2007 Sep 01; 100(5):855-9. PubMed ID: 17719333 [Abstract] [Full Text] [Related]